| Literature DB >> 31063087 |
A Farkas1, F Lin1, K Bui2, F Liu2, G L An2, A Pakholskiy1, C F Stavropoulos3, J C Lantis4, A Yassin2.
Abstract
Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) have been considered prevalent pathogens in foot infections. However, whether empiric therapy directed against these organisms is necessary, and in whom to consider treatment, is rather unclear. The aim of this study was to develop predictive algorithms for forecasting the probability of isolating these organisms in the infected wounds of patients in a population where the prevalence of resistant pathogens is low. This was a retrospective study of regression model-based risk factor analysis that included 140 patients who presented with infected, culture positive foot ulcers to two urban hospitals. A total of 307 bacteria were identified, most frequently MRSA (11.1%). P. aeruginosa prevalence was 6.5%. In the multivariable analysis, amputation (odds ratio (OR) 5.75, 95% confidence interval (CI) 1.48-27.63), renal disease (OR 5.46, 95% CI 1.43-25.16) and gangrene (OR 2.78, 95% CI 0.82-9.59) were identified as risk factors associated with higher while diabetes (OR 0.07, 95% CI 0.01-0.34) and Infectious Diseases Society of America infection severity >3 (OR 0.18, 95% CI 0.03-0.65) were associated with lower odds of P. aeruginosa isolation (C statistic 0.81). Similar analysis for MRSA showed that amputation was associated with significantly lower (OR 0.29, 95% CI 0.09-0.79) risk, while history of MRSA infection (OR 5.63, 95% CI 1.56-20.63) and osteomyelitis (OR 2.523, 95% CI 1.00-6.79) was associated with higher odds of isolation (C statistic 0.69). We developed two predictive nomograms with reasonable to strong ability to discriminate between patients who were likely of being infected with P. aeruginosa or MRSA and those who were not. These analyses confirm the association of some, but also question the significance of other frequently described risk factors in predicting the isolation of these organisms.Entities:
Keywords: Diabetes; MRSA; Pseudomonas aeruginosa; foot ulcer; resistance; stewardship
Mesh:
Year: 2019 PMID: 31063087 PMCID: PMC6518461 DOI: 10.1017/S0950268818003667
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Baseline demographics and comorbid conditions in the chronic foot infection population surveyed
| Variable (%) | Total | No DM | Yes DM | |
|---|---|---|---|---|
| 140 | 31 (22.2) | 109 (77.8) | – | |
| Gender | ||||
| Male | 67.9 | 61.3 | 69.7 | 0.503 |
| Age (years) | 64 (56, 73) | 70 (61, 76) | 62 (55, 72) | 0.028 |
| IDSA infection severity >3 | 37.9 | 32.3 | 39.4 | 0.604 |
| Charlson comorbidity index score | 4 (3, 6) | 3 (2.5, 4) | 5 (3, 6) | 0.002 |
| Gangrene | 26.4 | 16.1 | 29.4 | 0.214 |
| Previous admission | 17.1 | 25.8 | 14.7 | 0.238 |
| 13.6 | 22.6 | 11.0 | 0.134 | |
| MRSA | 23.7 | 23.3 | 23.9 | 1.000 |
| PVD | 30.2 | 9.68 | 36.1 | 0.009 |
| HbA1c (mmol/mol) | 9 (6.8, 10.9) | 5.85 (5.65, 6.45) | 10 (7.4, 11.1) | <0.001 |
| Immunosuppression | 2.86 | 6.45 | 1.83 | 0.213 |
| Amputation | 38.8 | 12.9 | 46.3 | 0.002 |
| Antibiotic prior to culture collection | 119 (85) | 24 (80) | 95 (87) | 0.294 |
| Total days of inpatient antibiotics | 8 (6, 12) | 7 (5.5, 8) | 9 (6, 13) | 0.011 |
| LOS in hospital (days) | 9 (6, 13) | 8 (6, 10.5) | 9 (7, 15) | 0.074 |
DM, diabetes mellitus; MRSA, Methicillin-resistant Staphylococcus aureus; PVD, peripheral vascular disease; HbA1c, haemoglobin A1c.
N is the number of patients. Data are shown as the median (interquartile range) or percentage of total. Immunosuppression is defined as HIV+, active chemotherapy or chronic high dose steroids.
Specimen description and overall prevalence of pathogens from the studied population
| Variable | Total, |
|---|---|
| Type of specimen included from subjects | |
| Bone | 55 (39.3) |
| Tissue biopsy | 70 (50) |
| Swab | 15 (10.7) |
| Bacteria | |
| Gram-positive bacteria | |
| 24 (8.0) | |
| 34 (11.1) | |
| 27 (8.7) | |
| 26 (8.4) | |
| 10 (3.2) | |
| Gram-negative bacteria | |
| Non-ESBL producing | 10 (3.2) |
| ESBL producing | 7 (2.2) |
| 20 (6.5) | |
| 19 (6.1) | |
| 16 (5.2) | |
| 8 (2.6) | |
| Anaerobic bacteria | |
| 13 (4.2) | |
| Other, Gram-positive bacteria | |
| Aerobe | 25 (8.2) |
| Anaerobe | 20 (6.6) |
| Other, Gram-negative bacteria | |
| Aerobe | 37 (12.2) |
| Anaerobe | 11 (3.6) |
| Total | 307 |
ESBL, extended spectrum beta-lactamase.
Swab specimens were collected according to recommendations in ref. [9].
Results of the univariable analysis of potential risk factors
| Predictor | MRSA | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Gender, male | 0.78 | 0.29–2.25 | 0.64 | 0.62 | 0.26–1.51 | 0.28 |
| Weight | 0.99 | 0.96–1.01 | 0.29 | 0.98 | 0.96–1.00 | 0.19 |
| Initial lactate | 0.96 | 0.37–1.71 | 0.90 | 1.49 | 0.90–2.62 | 0.11 |
| Ulcer surface area (cm2) | 1.08 | 0.99–1.21 | 0.11 | 0.97 | 0.83–1.07 | 0.72 |
| IDSA infection severity >3 | 0.27 | 0.06–0.85 | 0.50 | 0.18–1.25 | 0.15 | |
| Initial ESR | 1.00 | 0.98–1.02 | 0.98 | 1.00 | 0.99–1.02 | 0.23 |
| Initial CRP | 1.00 | 0.98–1.01 | 0.68 | 1.00 | 0.99–1.01 | 0.30 |
| Gangrene | 2.99 | 1.09–8.15 | 0.57 | 0.18–1.54 | 0.30 | |
| Previous admission | 1.92 | 0.57–5.70 | 0.26 | 1.50 | 0.49–4.09 | 0.43 |
| Sepsis on admission | 0.59 | 0.13–1.94 | 0.43 | 0.72 | 0.22–1.96 | 0.55 |
| PVD | 1.08 | 0.35–2.96 | 0.89 | 1.28 | 0.54–3.11 | 0.58 |
| Vascular insufficiency | 1.52 | 0.46–4.44 | 0.46 | 0.64 | 0.17–1.87 | 0.45 |
| DM | 0.42 | 0.15–1.24 | 0.10 | 0.99 | 0.37–2.94 | 0.99 |
| Renal disease | 2.40 | 0.88–6.48 | 0.08 | 1.21 | 0.47–2.91 | 0.67 |
| Amputation | 3.11 | 1.16–8.91 | 0.37 | 0.12–0.94 | ||
| ICU LOS | 0.95 | 0.48–1.24 | 0.80 | 0.99 | 0.67–1.24 | 0.98 |
| Charlson comorbidity index score | 1.20 | 0.99–1.46 | 0.06 | 0.95 | 0.78–1.14 | 0.61 |
| HbA1c | 0.81 | 0.49–1.17 | 0.31 | 1.09 | 0.83–1.43 | 0.52 |
| Smoking history | 1.43 | 0.31–5.02 | 0.60 | 1.91 | 0.56–5.75 | 0.26 |
| Nursing home resident | 0.11 | 0.00–1.57 | 0.13 | 1.8 | 0.47–5.25 | 0.28 |
| History of | 2.73 | 0.37–13.82 | 0.25 | 0.68 | 0.03–4.25 | 0.73 |
| History of MRSA infection | 0.56 | 0.03–3.13 | 0.58 | 5.09 | 1.46–17.82 | |
| Prior antibiotic course | 2.08 | 0.67–5.9 | 0.18 | 1.18 | 0.39–3.14 | 0.74 |
| Osteomyelitis | 0.83 | 0.31–2.20 | 0.70 | 1.79 | 0.76–4.38 | 0.18 |
| Immunosuppression | 0.35 | 0.01–7.57 | 0.51 | 0.27 | 0.01–5.41 | 0.40 |
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PVD, peripheral vascular disease; DM, diabetes mellitus; LOS, length of stay; HbA1c, haemoglobin A1c; MRSA, Methicillin-resistant Staphylococcus aureus.
Statistically significant P values are in bold.
Immunosuppression is defined as HIV+, active chemotherapy or chronic high dose steroids.
Summary of the top five best fit models for P. aeruginosa and MRSA
| AIC | LL | LR | LR | |
|---|---|---|---|---|
| 95.75 | −41.87 | NA | NA | |
| IDSA infection severity >3 + gangrene + amputation + DM + renal disease + sepsis | 96.56 | −41.27 | 1.19 | 0.27 |
| IDSA infection severity >3 + gangrene + DM + renal disease + amputation + immunosuppression | 96.57 | −41.28 | 1.18 | 0.27 |
| IDSA infection severity >3 + gangrene + DM + renal disease + amputation + history of | 96.88 | −41.44 | 0.86 | 0.35 |
| IDSA infection severity >3 + gangrene + DM + renal disease + amputation + prior antibiotic course | 96.74 | −41.37 | 1.00 | 0.31 |
| 130.9 | −61.46 | NA | NA | |
| Osteomyelitis + amputation + history of MRSA infection + nursing home | 132.2 | −61.08 | 0.76 | 0.38 |
| Osteomyelitis + amputation + history of MRSA infection + smoking history | 132.1 | −61.05 | 0.80 | 0.36 |
| Osteomyelitis + amputation + history of MRSA infection + IDSA infection severity >3 | 131.8 | −60.95 | 1.10 | 0.29 |
| Osteomyelitis + amputation + history of MRSA infection + PVD | 132.4 | −61.11 | 0.52 | 0.46 |
Final models are in bold.
AIC, Akaike's information criteria; LL, log-likelihood; LR, likelihood ratio, all presented vs. the final model; DM, diabetes mellitus; PVD, peripheral vascular disease.
Immunosuppression is defined as HIV+, active chemotherapy or chronic high dose steroids.
Hosmer–Lemeshow χ2 statistic = 10.05, degrees of freedom = 8, P = 0.26.
Cessie–van-Howelingen–Copas–Hosmer goodness-of-fit test sum of squared errors = 19.6; expected value = 19.4; standard deviation = 0.19; studentised test statistic = 1.32, P value = 0.18.
Fig. 1.Nomogram to predict risk of isolation of P. aeruginosa (PSA) in the infected wound. Each predictor with the presence (‘Yes’) or absence (‘No’) of the condition can be mapped to the Points axis on top of the nomogram to determine how many points towards the predicted probability of PSA in the wound the patient receives for the particular condition. Then, the sum of all of these points can be referred to in the Total points axis. Last, based on the Total points, the probability of isolating PSA in the wound can be obtained by drawing a straight line down to the corresponding Risk of isolation of PSA in wound axis. As an example, a patient presenting with gangrene (38 points for ‘Yes’ or 0 for ‘No’ on the Gangrene axis), an IDSA severity category of 3 (65 points for ‘No’ or 0 for ‘Yes’ on the IDSA Severity >3 axis), with amputation (66 points for ‘Yes’ or 0 for ‘No’ on the Amputation axis), who is not a diabetic (100 points for ‘No’ or 0 for ‘Yes’ on the Diabetes axis) and with chronic kidney disease (64 points for ‘Yes’ or 0 for ‘No’ on the Renal disease axis) would achieve a score of 333 (sum of all points for the individual risk factors), which then is referred to on the Total points axis, indicating a probability of isolating PSA in the wound of approximately 0.95 on the Risk of isolation of PSA in wound axis. In context with the measures of our model's discriminative ability, the case is then categorised into a predicted positive for PSA isolation in the wound when the estimated probability equals to or exceeds 0.19 (grey circle, which equals to 162 on the Total Points axis indicated by the grey arrow) vs. a negative for PSA isolation in the wound when the calculated probability is below the value of 0.19.
Fig. 2.Nomogram to predict risk of isolation of MRSA in the infected wound. To establish risk of isolation of MRSA in the wound, the steps outlined in Figure 1 should be followed using the predictors and respective point values assigned to the presence or the absence of a condition (53 points for ‘Yes’ or 0 for ‘No’ on the Osteomyelitis axis; 72 points for ‘No’ or 0 for ‘Yes’ on the Amputation axis; and 100s point for ‘Yes’ or 0 for ‘No’ on the Previous MRSA infection axis). Then, after summing the individual point values to establish the value for total points, categorise the case into a predicted positive for MRSA isolation in the wound when the estimated probability equals to or exceeds 0.29 (grey circle which equals to 122 on the Total points axis indicated by the grey arrow) vs. a negative for MRSA isolation in the wound when the calculated probability is below the value of 0.29.